

HEMATOLOGY

PFIZER ONCOLOGY

Researchers estimate that **by 2020**, nearly **412,000 people worldwide** will be diagnosed with some form of leukemia¹ and nearly **537,000 will be diagnosed with lymphoma**.² Many who are currently affected by these blood cancers are in need of new treatment options.

Developing Innovative Treatments for Blood Cancers

With marketed and investigational therapies, Pfizer is working to overcome the challenges of hematologic cancers and deliver innovative treatments to patients. Combating this formidable and complex set of hematologic diseases will require Pfizer to investigate a wide array of approaches, including collaborations with industry, academic and community partners to study multiple paths to advancing treatment.

LEUKEMIA

Leukemia can be categorized based on which type of white blood cell is involved (lymphocytes or myeloid cells) as well as whether the illness is chronic (developing slowly and persisting for a long time) or acute (developing very quickly).³



Lymphocytic leukemias develop from cells that give rise to **T lymphocytes** (T cells), **B lymphocytes** (B cells) or **natural killer cells**, each of which has a role in the immune system.³




Myeloid leukemias develop from cells that give rise to **white blood cells** called **granulocytes** or **monocytes**.³

Pfizer's marketed and investigational products aim to treat different types of leukemias including:

Chronic Myeloid Leukemia (CML)

CML accounts for **10-15% of all incident leukemia cases worldwide**^{4,5}


Approximately **51,500 people** are living with CML⁶



Acute Myeloid Leukemia (AML)

AML is the **most common form of leukemia in adults**, accounting for approximately a third of all leukemias worldwide⁷


In 2012, the worldwide incidence of AML was estimated to be **351,965**⁸



Acute Lymphoblastic Leukemia (ALL)

ALL accounts for approximately **12% of all leukemia cases worldwide**⁹

For adult patients with relapsed or refractory ALL, the five-year overall survival rate is **less than 10%**^{10,11}



LYMPHOMA

Lymphoma is a type of cancer that originates in the part of the body's immune system known as the lymphatic system, which includes the lymph nodes and lymphoid tissues.¹²

Pfizer is currently investigating medicines with the potential to treat different types of lymphomas including:

Non-Hodgkin Lymphoma (NHL)

There were **386,000 new cases of NHL** diagnosed in 2012¹³



The five-year **survival rate** for NHL is approximately **71%**¹⁴



Pfizer Products

Pfizer has four therapies approved worldwide to treat various types of blood cancers, as well as several therapies in clinical development.



Note: products listed in pipeline snapshot are not currently approved for these indications by the U.S. Food and Drug Administration; pipeline as of May 2018

Pfizer's Commitment to Patient Support



Pfizer is committed to making investigational or unlicensed products available under our compassionate use policy to seriously ill patients who have exhausted other treatment options.

Pfizer's Partnerships



At Pfizer, we know collaboration is the key to success in developing innovative treatments. That's why we've built **partnerships with the world's leading scientific institutions** and **patient advocacy groups** with the goal of **improving lives for patients** living with hematologic malignancies.

- GLOBOCAN Online Analysis/Prediction. Available at: http://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Text-p=World&selection_cancer=12280&Text-c=Leukaemia&pYear=8&type=0&window=1&submit=%C2%A0Execute. Accessed June 2018.
- GLOBOCAN Online Analysis/Prediction. Available at: http://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Text-p=World&selection_cancer=19260&selection_cancer=8250&Text-c=Non-Hodgkin+lymphoma%2C+Hodgkin+lymphoma&pYear=8&type=0&window=1&submit=%C2%A0Execute. Accessed June 2018.
- Memorial Sloan Kettering Cancer Center. Types of leukemia. Available at: <https://www.mskcc.org/cancer-care/types/leukemias/types>. Accessed June 2018.
- American Cancer Society. Chronic myeloid leukemia detailed guide. Available at: <https://www.cancer.org/cancer/chronic-myeloid-leukemia.html>. Accessed June 2018.
- Hochhaus, A. Educational Session: Managing chronic myeloid leukemia as a chronic disease. *American Society of Hematology*. 2011; 10: 1.
- National Cancer Institute. Surveillance epidemiology and end results (SEER) statistics stratified by cancer site: Chronic myeloid leukemia prevalence. Available at: <http://seer.cancer.gov/faststats/selections.php?run=runit&output=2&data=5&statistic=9&race=1&sex=1&age=1&series=cancer&cancer=97>. Accessed June 2018.
- Deschler B et al. Acute myeloid leukemia: epidemiology and etiology. *Cancer*. 2006. 2009-2017.
- World Health Organization. 2014 Review of cancer medicines on the WHO list of essential medicines. Available at: http://www.who.int/selection_medicines/committees/expert/20/applications/AML_APL.pdf. Accessed June 2018.
- Redaelli I, A., et al. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). *European Journal of Cancer Care*, 2005 14: 53–62. doi: 10.1111/j.1365-2354.2005.00513.x
- Fielding A. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. *Blood*. 2006; 944-950.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: acute lymphoblastic leukemia. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed June 2018.
- SEER. SEER stat fact sheets: Hodgkin Lymphoma. Available at: <http://seer.cancer.gov/statfacts/html/hodg.html>. Accessed June 2018.
- Cancer Research UK. Non-Hodgkin Lymphoma incidence statistics. Available at: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma/incidence#heading-Nine>. Accessed June 2018.
- SEER. SEER stat fact sheets: Non-Hodgkin's Lymphoma. Available at: <http://seer.cancer.gov/statfacts/html/nhl.html>. Accessed June 2018.